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The most commonly used drugs for the treatment of ventricular tachyarrhythmias are quinidine, procainamide, and lignocaine. The most effective of these drugs, lignocaine, fails, however, in terminating ventricular arrhythmias in up to 20 per cent of the affected patients (Bigger and Heissenbuttel, I969; Harrison and Alderman, I972) . There are also other drawbacks with these antiarrhythmic drugs. Side effects such as depression of myocardial contractility, hypotension, and conduction abnormalities have especially been described with the use of quinidine and procainamide but can be seen with other drugs (Mason et al., I973). Lignocaine is short acting and repeated injections or continuous intravenous infusion are required (Harrison and Alderman, I972) . N,N-bis (phenylcarbamoylmethyl) dimethylammonium chloride (QX-572) is a quaternary ammonium compound and a lignocaine derivative (Fig. i) . In previous studies this new antiarrhythmic Received I5 January, I974.
3 QX-572 manufactured and supplied by Astra (Sodertlije, Sweden) . 2 Present address: Department of Cardiology, All India Institute of Medical Sciences, New Delhi i6, India. drug was found to be effective against ventricular arrhythmias in animals (Covino and Rachwall, I964; Katz, I964; Madan, Khanna, and Madan, I967) as well as in man (Katz, I965;  Schwartz, Stapleton, and Covino, I967) . Interest in the drug faded at that time probably because it has to be administered intravenously. This is because of its nature as a quaternary ammonium compound (Goodman and Gilman, I970) . Despite this limitation, such an antiarrhythmic agent might still be of value within a coronary care unit. The present investigation was undertaken to study the effect of QX-572 in patients with ventricular tachyarrhythmia, caused mainly by acute myocardial infarction, and resistant to common antiarrhythmic drugs, especially lignocaine. It was felt that QX-572 could have specific advantages by being very potent and long acting. Another advantage might be that the drug as a quaternary ammonium compound does not penetrate the blood brain barrier (Goodman and Gilman, I970).
Subjects and methods
The drug was studied in I2 A 68-year-old man with moderate hypertension, coronary heart disease, and a myocardial infarction two months before admission to hospital had a new myocardial infarction which was complicated by repetitive multifocal ventricular ectopic beats often in bigeminy. The ectopic beats persisted also during lignocaine infusion (2-3 mg/min) as well as when diphenylhydantoin was given (oral dose 0o3 g daily). The patient did not tolerate procainamide (rash) or quinidine (diarrhoea). QX-572 8 mg/kg body weight was planned to be infused during 30 minutes, but the infusion was stopped after 25 minutes (=6'7 mg/kg) as right bundle-branch block appeared. This persisted for 6 hours. The patient had shown intermittent bundle-branch block on several earlier occasions. The effect of QX-572 on the ectopic beats is shown in Fig. 3 (Fig. 4) and returned thereafter with similar frequency.
Case 4
A 34-year-old man with subvalvar aortic stenosis caused by obstructive cardiomyopathy, had postextrasystolic pressure gradient across the aortic valve of go mmHg. He showed numerous multifocal ventricular premature beats mostly as bigeminy and had short bursts of ventricular tachycardia. Alprenolol (oral dose o04 g daily) and practolol (30 mg intravenously) did not influence the arrhythmias. Procainamide produced dizziness and paraesthesia, and quinidine could not be given because of diarrhoea. QX-572 was infused with good response (Fig. 5) lasting for i6 hours. Later the patient was given ajmaline with satisfactory reduction in frequency of the ventricular premature beats.
Case 5
A 66-year-old man was admitted with acute myocardial infarction and frequent ventricular premature beats. Lignocaine (300 mg intramuscular) had a short-lasting effect (20 minutes). The arrhythmia reappeared and a short run of ventricular tachycardia was also noted. Intravenous lignocaine (ioo mg bolus followed by Case 6 A 59-year-old man developed ventricular tachycardia I2 days after an acute myocardial infarction. The onset was preceded by multiple ventricular premature beats which could not be suppressed with lignocaine (4 mg/min supplemented with bolus injections) though the patient had convulsions. Procainamide (o 5 g intravenously) produced hypotension but the ventricular tachycardia persisted. Twenty minutes after the start of an infusion of QX-572 the ventricular tachycardia was abolished. Sinus rhythm was maintained for about 4 hours when ventricular bigeminy appeared. However, further QX-572 (4 mg/kg) restored sinus rhythm for another 3 hours.
When ventricular ectopic beats again reappeared, QX-572 (2 mg/kg) was effective for only one hour (Fig. 7) . Ventricular tachycardia reappeared later. Different ways were subsequently tried to stop the tachycardia. Practolol (30 mg intravenously) did not affect the rhythm nor did ajmaline (50 mg intravenously), lignocaine (4 mg/min supplemented with bolus injections of IOO mg), or quinidine (I-2 g daily) which produced anorexia when used for two days. With DC cardioversion the patient responded only to 400 joules, and stable sinus rhythm was obtained for just a few minutes. Since other antiarrhythmic agents were ineffective, further injections of QX-572 were administered. Each time the antiarrhythmic effect was almost predictable as described above, with an initial response to 8 mg/kg. An additional dose of QX-572 was needed after 4 hours. The ventricular tachycardia subsided after 6 days. During that time the patient had received totally 2-962 g of QX-572 (three times 8 mg/kg, three times 4 mg/kg, and once 2 mg/kg). The patient received digoxin (0-25 mg daily, serum level 2@3 ng/ml with the red cell 86Rb technique) when developing the ventricular tachycardia. The arrhythmia was finally interpreted as induced by digitalis.
Case 7
A 52-year-old man with left ventricular aneurysm after an acute myocardial infarction was admitted to hospital because of left ventricular failure and ventricular fibrillation. After DC conversion there were frequent ventricular premature beats not responding to lignocaine (4 mg/min supplemented by several bolus injections). QX-572 was administered initially without effect. At that time serum potassium was found to be low (2-7 mEq/l.). Infusion of potassium was started and the ectopic beats disappeared. The patient was on digitalis therapy and the arrhythmia was thought to depend on increased digitalis sensitivity caused by low serum potassium. However, quite frequent ventricular ectopic beats remained during the following days despite normal serum potassium and withdrawal of digitalis. This arrhythmia was resistant to lignocaine (4 mg/min which gave a serum level of 7-2 jig/ml). Lignocaine was withdrawn and a new trial with QX-572 was performed. The response was favourable for five hours. At that time the ectopic beats reappeared. Lignocaine was now effective up to i8 hours after the start of QX-572 infusion (Fig. 8) About three weeks later she was readmitted because of syncope. The electrocardiogram showed ventricular ectopic beats and short bursts of ventricular tachycardia.
Lignocaine (4 mg/min supplemented with bolus injections) and procainamide (oral dose i-o g) did not affect the arrhythmia. QX-572 was infused (planned dose 8 mg/kg=6oo mg) and lignocaine withdrawn. After 270 mg QX-572, the patient had nausea and vomited. Immediately afterwards the blood pressure fell to a systolic pressure of 65 mmHg and the heart rate was reduced from 87 to 70 beats/min. The injection of QX-572 was stopped and the legs were raised. Five minutes later the blood pressure returned to normal. No ectopic beats were seen during three and a half hours. At that time ventricular ectopic beats and tachycardia reappeared. A second injection of 330 mg QX-572 was given to complete the planned total dose. This time there was only a slight fall in blood pressure and the heart rate increased somewhat. After the second QX-572 infusion the arrhythmia totally disappeared for another 2 hours. Thereafter ventricular ectopic beats reappeared and one run of ventricular tachycardia was recorded. Lignocaine (2 to 4 mg/min), which had previously been ineffective, now abolished the arrhythmia during the remaining part of the observation period of 24 hours. A left ventricular aneurysm complicating the first myocardial infarction was suspected.
Case 9 A 69-year-old man with previous hypertension developed acute myocardial infarction. The first day ventricular arrhythmia appeared and responded to lignocaine. When the infusion rate exceeded 2 mg/min the patient showed cerebral side effects in the form of confusion, agitation, drowsiness, and seizures. On the twelfth day the patient had attacks of ventricular tachycardia without frequent preceding ventricular ectopic beats. Lignocaine proved effective only in a dosage of 3 to 4 mg/min but was again followed by cerebral side effects. When infusion was reduced ventricular tachycardia reappeared. During the next 4 days lignocaine induced cerebral side effects when an amount sufficient to suppress the arrhythmia was used. Finally QX-572 was infused and lignocaine was withdrawn. No further ventricular arrhythmias were noted. Quinidine (I2 g daily) was started 12 hours after QX-572 and proved effective.
Case IO
A 54-year-old man with one earlier myocardial infarction was admitted with an acute anterior infarction complicated by left ventricular failure. Digitalis and diuretics were administered. The patient improved, but on the fifth day after infarction he developed ventricular tachycardia. The only effect of various antiarrhythmic agents administered intravenously was a reduction of ventricular rate after ajmaline (Fig. 9) . DC conversion was not used as digitalis was suspected to be the cause of the arrhythmia. Twenty minutes after the start of QX-572 infusion sinus rhythm was restored. The arrhythmias did not return.
Case ii A 67-year-old man, without earlier signs of cardiac disease, developedventricular ectopic beats which initially responded to quinidine (I2 g daily). Five months later the patient deteriorated. At this time there were numerous multifocal ventricular ectopic beats and runs of ventricular tachycardia. Diphenylhydantoin (oral dose o-6 g daily) was added with effect only for a few days. These drugs were then withdrawn and intravenous antiarrhythmic treatment was started. Lignocaine (4 mg/ min supplemented with bolus injections) did not prevent the arrhythmias. (0-2 g), practolol (I5 mg), ajmaline (50 mg), diphenylhydantoin (0.25 g), were added successively to the lignocaine infusion but had no effect. Finally the patient developed persistent ventricular tachycardia. QX-572 was then infused. Sinus rhythm was restored 20 minutes after the start of the infusion and remained for more than 20 hours though some ventricular ectopic beats occurred after I3 hours. When the patient again developed persistent ventricular tachycardia 48 hours after the first QX-572 infusion (Fig. io) , another infusion was given with similar good result.
Case I2
A 63-year-old man with hypertension had an acute myocardial infarction with ventricular tachyarrhythmia. ectopic beats were seen during the following 28 hours. The ectopic beats and runs of ventricular tachycardia then reappeared. Lignocaine was reinstituted and combined with diphenylhydantoin (o025 g intravenously).
This did not prevent some further attacks of ventricular fibrillation. QX-572 was then once more administered.
During the next 6 hours short runs of ventricular tachycardia occurred twice. There were also some ventricular premature beats. Ventricular fibrillation, however, did not recur. Later quinidine and diphenylhydantoin was administered orally in combination. This regimen kept the ventricular arrhythmia under control.
To summarize the results (Table) , QX-572 was injected 22 times in I2 patients with ventricular arrhythmias resistant to conventional treatment. In 7 patients (Cases I, 2, 5, 6, 9, I0, I2) the arrhythmias were caused by coronary heart disease complicated by acute myocardial infarction. In 2 of these cases (Cases 6 and io) digitalis toxicity and in one (Case 7) 'digitalis toxicity due to hypokalaemia were considered the important arrhythmiaprovoking factors. (Covino, I962; D'Amato and Truant, I962; Katz, i963, i964; Madan et al., i967) . It was also shown that intracoronary infusion of QX-572 in dogs produced a positive inotropic effect and increased cardiac output and coronary blood flow (Katz, i963) . Covino and Rachwall (i964) studied the influence of the drug on isolated papillary muscles as well as in intact animals. They stated that QX-572 increased the diastolic threshold potential and prolonged the refractory period. They also noted a decrease in myocardial conduction velocity. QX-572 prolonged the refractory period more than quinidine while the increase in diastolic threshold potential was more pronounced after quinidine. Conduction velocity was lower after quinidine than QX-572 but decreased after both drugs.
Earlier clinical studies in man demonstrated that QX-572 was ineffective in the termination of chronic atrial fibrillation (Schwartz et al., I967 (Schwartz et al., I967) . The most common side effect noted in these studies referred to was circumoral paraesthesia. Tachycardia was noted in some patients as well as moderate hypotension. The development of hypotension was thought to be related to the vasodilating action of QX-572 demonstrated earlier in animal studies (Schwartz et al., i967) .
The present study confirms earlier reports of QX-572 as a potent agent against ventricular tachyarrhythmias. The antiarrhythmic effect of QX-572 in these rather malignant arrhythmias was obvious. In cases where repeated infusions were given reproducible response was obtained. All the patients in this study were treated with other antiarrhythmic agents before QX-572 was tried. In this study QX-572 was often given against lifethreatening ventricular tachyarrhythmias. It was, therefore, not possible to require that earlier drugs should be totally excreted before QX-572 was given. Actually QX-572 was considered life saving in some of the present cases. Furthermore, the antiarrhythmic effect of QX-572 was found to be of long duration. This makes it reasonable to believe that possible effects of previously given antiarrhythmic drugs could be excluded. The long duration of action of QX-572 has been noted earlier (Schwartz et al., i967) . This has also been found for other quaternary ammonium compounds (D'Amato and Truant, I962). The side effects of QX-572 noted here are in accordance with earlier findings. In the present study it should be noticed that many patients were in a poor clinical condition when receiving QX-572. This makes it difficult to evaluate the background for and importance of the observed reactions in blood pressure and heart rate. In some patients the correlation between these haemodynamic side effects and QX-572 was uncertain. The observed side effects were furthermore not considered of great clinical importance. A more pronounced fall in blood pressure has been described earlier in some patients (Katz, I965; Schwartz et al., I967) . It was, therefore, considered important to inject the drug very slowly when the present study was planned. The slow rate of QX-572 infusion obviously reduced the risk of blood pressure drop. The mechanism behind the substantial increase in blood pressure observed once in one patient after completion of QX-572 infusion is unknown. A slight tendency to a blood pressure increase after a completed QX-572 infusion has been observed also in some of the other patients, which might indicate a correlation between QX-572 and this blood pressure reaction.
Overdrive is a well-known technique in the treatment of ventricular tachyarrhythmia. Usually the heart rate increased when the drug was given. However, there does not seem to be any correlation between the tachycardia, blood pressure changes, and the antiarrhythmic effect of QX-572. That the antiarrhythmic effect remains after the heart rate returns to normal also indicates that the heart rate effect per se does not contribute to the antiarrhythmic effect of the drug.
Since QX-572 as a quaternary ammonium compound is not absorbed orally, the use of the substance has earlier been considered to be of limited value (Schwartz et al., I967) . However, the potency of QX-572 in therapy resistant ventricular tachyarrhythmias, its long duration of action, and apparent lack of dangerous side effects at therapeutically effective dosage, even in patients with a severely damaged myocardium, may make this drug a useful addition in the treatment of ventricular arrhythmias especially in coronary care units or during cardiovascular surgery.
A final judgment of QX-572 should, however, not be based only upon studies such as the present. For more valid conclusions concerning its antiarrhythmic activity and possible drawbacks controlled studies have to be performed. Such studies are in progress as well as studies on the electrophysiological and haemodynamic properties of the drug. The metabolism of the compound and the pharmacokinetics of its action are also under investigation.
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